Competitive Indication Landscape

Population

• Source field: trial_details_information.meddraConditionTerms — a JSON array per trial of MedDRA terms (multi-level: SOC / HLGT / HLT / PT / LLT).
• Granularity: only entries with level = "PT" (Preferred Term, the most specific clinically-actionable level). SOC/HLGT/HLT levels are ignored — too broad for sponsor competition analysis.
• Visibility filter: HAVING COUNT(DISTINCT trial_id) >= 5. Conditions with fewer than 5 trials are hidden (1,168 rarer PT terms, total 1,441 in CTIS) — pipeline signal too weak.
• All trial statuses included: this is a pipeline view, so active, recruiting, ended, halted etc. all count.

Per-condition metrics

• Trials = COUNT(DISTINCT trial_id) for this PT. A trial listing the same PT twice in meddraConditionTerms is counted once (this fixed a small previous double-counting issue).
• Recruiting = COUNT(DISTINCT trial_id WHERE ctPublicStatusCode IN ('3','4')). Same DISTINCT semantic — trials are counted once regardless of how many times the term repeats.
• Recruiting % (the green bar) = recruiting / trials × 100.

Why "distinct trials with PT" is lower than total CTIS trials

The 4,359 figure in the hero counts trials that have any MedDRA PT-level term, deduplicated across all PTs (one trial → one count). It is lower than the global CTIS trial count because some trials are coded only at SOC / HLGT level, with no PT entry.

The visible cards sum to 4,317 trial-PT pairs — that's larger than 4,359 because a trial coded under multiple PTs (e.g. "Breast cancer" + "Triple negative breast cancer") appears in every relevant card. Each card is its own competitive view; summing across cards is not meaningful for trial totals.

Caveats

• MedDRA PT terms cover overlapping clinical concepts (e.g. several breast-cancer subtypes). A given trial can legitimately appear under several cards.
• PT classification is sponsor-supplied at registration time. Misclassification or outdated MedDRA versions in the source registry will propagate here.
• Hidden conditions (< 5 trials) include both genuinely-rare diseases and brand-new indications still ramping up — the threshold is a visibility convenience, not a clinical statement.